Clinical Trials
3 trialsNCT02921828 2022-07-05
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene
Completed
NCT03099031 2019-12-16
PREDICARE
LEO Pharma
Completed
NCT00433602 2013-06-12
Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Completed